Liposome-based dry powder vaccine immunization targeting the lungs induces broad protection against pneumococcus
Journal of Controlled Release · 2024-04 · 368 · 184-198
DOI: 10.1016/j.jconrel.2024.02.028 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2024-04. Verfasst von T C Rodrigues und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratório de Bacteriologia, Instituto Butantan, São Paulo, Brazil; Programa de Pós-Graduação Interunidades em Biotecnologia, Universidade de São Pa…. Hauptthemen laut MEDLINE: Streptococcus pneumoniae, Pneumococcal Infections, Galactosylceramides. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, National Council for Scientific and Technological Development, UKRI Medical Research Council.
Abstract (Originalsprache)
Streptococcus pneumoniae is an important human pathogen. Currently used conjugate vaccines are effective against invasive disease, but protection is restricted to serotypes included in the formulation, leading to serotype replacement. Furthermore, protection against non-invasive disease is reported to be considerably lower. The development of a serotype-independent vaccine is thus important and Pneumococcal surface protein A (PspA) is a promising vaccine candidate. PspA shows some diversity and can be classified in 6 clades and 3 families, with families 1 and 2 being the most frequent in clinical isolates. The ideal vaccine should thus induce protection against the two most common families of PspA. The aim of this work was to develop a liposome-based vaccine containing PspAs from family 1 and 2 and to characterize its immune response. Liposomes (LP) composed of dipalmitoylphosphatidylcholine (DPPC) and 3β-[N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol (DC-Chol) with or without α-galactosylceramide (α-GalCer) were produced by microfluidics, encapsulating PspA from clade 1 (PspA1, family 1) and/or clade 4 (PspA4Pro, family 2) followed by spray-drying with trehalose to form nanocomposite microparticles carriers (NCMP). LP/NCMPs showed good stability and preservation of protein activity. LP/NCMPs containing PspA1 and/or PspA4Pro were used for immunization of mice targeting the lungs. High serum IgG antibody titers against both PspA1 and PspA4Pro were detected in animals immunized with LP/NCMPs containing α-GalCer, with a balance of IgG1 and IgG2a titers. IgG in sera from immunized mice bound to pneumococcal strains from different serotypes and expressing different PspA clades, indicating broad recognition. Mucosal IgG and IgA were also detected. Importantly, immunization with LP/NCMPs induced full protection against strains expressing PspAs from family 1 and 2. Furthermore, CD4+ resident memory T cells were detected in the lungs of the immunized animals that survived the challenge.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratório de Bacteriologia, Instituto Butantan, São Paulo, Brazil; Programa de Pós-Graduação Interunidades em Biotecnologia, Universidade de São Paulo, São Paulo, Brazil.
- Programa de Pós-Graduação Interunidades em Biotecnologia, Universidade de São Paulo, São Paulo, Brazil; Laboratório de Desenvolvimento de Vacinas, Instituto Butantan, São Paulo, Brazil.
- School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, Merseyside, United Kingdom.
- School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, Merseyside, United Kingdom. Electronic address: I.Saleem@ljmu.ac.uk.
- Laboratório de Bacteriologia, Instituto Butantan, São Paulo, Brazil; Programa de Pós-Graduação Interunidades em Biotecnologia, Universidade de São Paulo, São Paulo, Brazil. Electronic address: eliane.miyaji@butantan.gov…
Förderung
- Medical Research Council
- National Council for Scientific and Technological Development
- UKRI Medical Research Council
- State of Sao Paulo Research Foundation
- Coordination of Higher Education Personnel Improvement
Zitieren
APA
Rodrigues, T. C., Figueiredo, D. B., Gonçalves, V. M., Kaneko, K., Saleem, I. Y., & Miyaji, E. N. (2024). Liposome-based dry powder vaccine immunization targeting the lungs induces broad protection against pneumococcus. Journal of Controlled Release, 368, 184-198. https://doi.org/10.1016/j.jconrel.2024.02.028
Vancouver
Rodrigues TC, Figueiredo DB, Gonçalves VM, Kaneko K, Saleem IY, Miyaji EN. Liposome-based dry powder vaccine immunization targeting the lungs induces broad protection against pneumococcus. Journal of Controlled Release. 2024;368:184-198. doi:10.1016/j.jconrel.2024.02.028
BibTeX
@article{Rodrigues2024,
author = {Rodrigues, T C and Figueiredo, D B and Gonçalves, V M and Kaneko, K and Saleem, I Y and Miyaji, E N},
title = {Liposome-based dry powder vaccine immunization targeting the lungs induces broad protection against pneumococcus},
journal = {Journal of Controlled Release},
year = {2024},
volume = {368},
pages = {184--198},
doi = {10.1016/j.jconrel.2024.02.028}
}
EUVIMED